What BMI is needed for Wegovy approval in the UK?

Does the BMI figure on the licence actually match what NHS Wegovy approval requires?

The short answer is no, there is a meaningful gap between the two. Wegovy's UK marketing authorisation covers adults with a BMI of 30 or above, or 27 or above alongside a qualifying condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. That is the licensed basis for private prescribing. The NHS picture is considerably narrower.

NICE's technology appraisal for semaglutide (TA875) recommends it only within specialist weight management services, for adults with a BMI of 35 or above and at least one weight-related comorbidity, for a maximum of two years. NICE TA875 also sets out that BMI thresholds are adjusted down by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, reflecting the higher health risks at lower BMI in those groups. NHS England applies this as 32.5 rather than 35 for the relevant cohorts.

What that means practically: someone with a BMI of 31 and well-controlled blood pressure is within the licensed range for private prescribing but almost certainly outside the NHS criteria. Someone at BMI 38 with hypertension and sleep apnoea might meet both. If you want a clear breakdown of which BMI thresholds Wegovy is actually approved for, our dedicated page covers the licensed and NHS brackets in detail. If you are wondering whether your BMI sits in the right range, the NHS BMI calculator is the fastest place to check.

If your BMI is between 27 and 29.9, does a comorbidity automatically qualify you?

Having a qualifying condition alongside a BMI in the 27–29.9 range puts you within the licensed eligibility window for Wegovy, but it does not make approval automatic. A prescriber still reviews your full clinical picture: the nature and severity of the condition, any contraindications, your medical history, and whether Wegovy is the most appropriate option given everything in front of them.

The qualifying conditions that count in this range are generally those where excess weight is making the condition harder to manage or is directly raising your risk, type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea, and established cardiovascular disease are the most commonly cited. Prediabetes may also be relevant; your prescriber will assess this.

People sometimes ask about a BMI just below 27 and whether anything changes that. BMI of 25 and Wegovy eligibility gets into the specifics of that boundary. The honest answer is that 27 is the licensed lower limit for the comorbidity route, and prescribers work within the licence for good clinical and legal reasons. If your BMI is 26.5 with a qualifying condition, the right conversation is with a prescriber rather than a checklist.

It is also worth noting that BMI alone never tells the full story of body composition or cardiovascular risk, a prescriber at our clinical team will look at the broader picture, not just a single number.

How does this differ from what NICE says about Wegovy on the NHS, and does it affect me?

It affects you if you are hoping to access Wegovy through your GP or an NHS specialist service, yes. The NICE-recommended pathway (TA875) requires a BMI of 35 or above, at least one weight-related condition, and enrolment in a multidisciplinary specialist service. Treatment is time-limited to two years under that recommendation. NHS waiting lists for specialist obesity services are commonly long, and eligibility is assessed by NHS teams who follow these stricter criteria.

For people who do not meet the NHS threshold, or who do not want to wait, private prescribing through a regulated pharmacy follows the licence criteria rather than the NICE recommendation. That is a legitimate route, the NICE criteria govern NHS commissioning, not whether a medicine can lawfully be prescribed privately. The clinical suitability assessment still happens; it is just conducted privately. If you are curious about whether Wegovy is an option at a normal BMI, we cover the evidence and the prescribing boundaries in detail.

If cost is a factor in your thinking, the cost of Wegovy in the UK page sets out what private treatment typically involves and what an all-inclusive price should cover. At nume, everything from consultation to next-working-day DPD delivery is included in one price, no separate prescription fee, no aftercare charges. Your pen arrives in plain packaging, tracked to your door.

One contextual note: Wegovy is a Black Triangle (▼) medicine, meaning the MHRA monitors it under additional pharmacovigilance. That is standard for newer medicines and does not change the eligibility criteria, but it is a reason to understand your treatment options thoroughly before starting.

What else does a prescriber consider beyond the BMI number?

The BMI thresholds open the door; the consultation is where a prescriber decides whether to walk through it with you. Several factors sit alongside BMI in that assessment.

Contraindications matter. Wegovy is not suitable for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A history of pancreatitis, or certain gastrointestinal conditions, will also prompt careful discussion. The medicine is not recommended for use during pregnancy or breastfeeding, or for anyone trying to conceive. These are not bureaucratic hurdles, they reflect genuine clinical risk.

Current medicines are also relevant. Wegovy slows gastric emptying, which can affect the absorption of other oral drugs taken at the same time. Oral contraceptives are one example where a prescriber will advise on timing or additional contraceptive cover during the early weeks of treatment.

If you have already tried a different weight-loss medicine and want to switch to Wegovy, your prescriber will want to understand your history with it, including how far through the dose schedule you got and why you are changing. People transferring from another provider are asked to provide evidence of their current treatment as part of our clinical process, that is patient safety, not red tape.

The consultation at nume's treatment page is free, reviewed the same day by a GPhC-registered prescriber (not software), and there is no obligation. If you are close to the BMI threshold and unsure, our guide to BMI for Wegovy is a useful starting point before you speak to a prescriber.